Charles Li
Fortuna: 275 088 $ al 31/05/2026
Fortuna: 275 088 $ al 31/05/2026
Dr. Charles Li is a Chief Business Officer at Angel Pharmaceuticals Co., Ltd. and an Independent Director at Ekso Bionics Holdings, Inc. He is on the Board of Directors at Ekso Bionics Holdings, Inc. He received his undergraduate degree from Xi'an Jiaotong University and a doctorate degree from John A Paulson School of Engineering & Applied Sciences.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
0,01 % | 20/02/2026 | 14.983 ( 0,01 % ) | 275 088 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
Angel Pharmaceuticals Co., Ltd.
Angel Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops medicines for treatment of cancer, autoimmune and infectious diseases | Corporate Officer/Principal | 10/10/2020 |
| Empresas | Cargo | Fin |
|---|---|---|
| EKSO BIONICS HOLDINGS | Director/Miembro de la Junta | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
| Empresas privadas | 4 |
|---|---|
Ekso Bionics Holdings, Inc.
Ekso Bionics Holdings, Inc. Medical SpecialtiesHealth Technology Operates as a robotic exoskeleton company, which designs and develops exoskeletons and wearable robots | Health Technology |
Xi'an Jiaotong University
Xi'an Jiaotong University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
John A Paulson School of Engineering & Applied Sciences
John A Paulson School of Engineering & Applied Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Angel Pharmaceuticals Co., Ltd.
Angel Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops medicines for treatment of cancer, autoimmune and infectious diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.